MedPath

Embolization for Meningioma

Not Applicable
Recruiting
Conditions
Meningioma
Interventions
Procedure: Endovascular embolization
Registration Number
NCT05416567
Lead Sponsor
St. Olavs Hospital
Brief Summary

The natural course for meningioma suggests that a majority will grow over time. Treatment is usually indicated in growing or symptomatic meningiomas. Surgery is usually primary treatment, but there is a significant risk of adverse effects. Stereotactic radiotherapy is most often reserved to treat relapses after surgery, and except for surgery and radiotherapy there are no other established treatment methods. Endovascular embolization may be used in selected cases as a preoperative adjunct to reduce intraoperative bleeding. There is a need for more treatment options in patients with meningioma, both in uncomplicated, asymptomatic cases and in more complex cases. The aim of this study is to assess radiological and clinical results of therapeutic endovascular embolization for meningioma

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
30
Inclusion Criteria
  • Radiological diagnose of typical intracranial meningioma (homogenous contrast enhancement or dural attachment)
  • Indication for treatment due to growth, symptoms or both
  • Tumor location suggestive of vascular supply via middle meningeal artery branches
  • Age 18 years or older
  • Karnofsky performance status of 90 or better (able to carry on normal activity and work)
Exclusion Criteria
  • Informed consent not possible (e.g. language barriers, aphasia, cognitive impaired)
  • Previously treated for meningioma
  • Intraosseous growth
  • Tumor related brain edema
  • Neurofibromatosis type 2
  • Systemic cancer
  • Epilepsy
  • Progressive neurodegenerative disorder (eg. MS, Parkinsons disease)
  • History of psychiatric disorder
  • Unfit for participation for any other reason judged by the physician including patients
  • Contraindications to MRI
  • Allergic to contrast agents
  • Relative contraindications to endovascular treatment judged from CT angiography (tortoise carotid arteries, carotid stenosis, calcified aortic arch, anatomical vascular variants/anomalies suggesting increased risk with endovascular treatment)
  • DSA (Digital subtraction angiography) from carotid artery suggesting that significant vascular supply is from other vessels than the MMA.

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Endovascular embolizationEndovascular embolization-
Primary Outcome Measures
NameTimeMethod
Change in radiological tumor volume from baselineAt 1 year, 3 year and 5 year

Volumetric segmentation of tumor volume

Secondary Outcome Measures
NameTimeMethod
Change in neurological functionAt 1 month

National Institutes of Health Stroke Scale (NIHSS)

Number of participants with adverse events30 days

Landriel Ibanez classification

Number of participants returning to workAt 1 months and 6 months
Number of participants undergoing re-intervention for meningioma or treatment complications10 years

Surgery or radiotherapy

Change in generic health-related quality of life from baselineAt 1 months and 6 months

EuroQol-5D 3L (EQ-5D 3L)

Change in domain-specific quality of life from baselineAt 1 months and 6 months

The European Organisation for Research and Treatment of Cancer (EORTC) QLQ-BN20 questionnaire

Number of participants with epileptic seizures10 years
Change in disease-specific quality of life from baselineAt 1 months and 6 months

The European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 questionnaire

Loss of functional level from baselineAt 1 month and 6 months

\>10 points in Karnofsky performance status

Number of participants with moderate or severe procedure related complications within 30 days30 days

Landriel Ibanez classification (grade 3 or 4 complications)

Trial Locations

Locations (1)

St Olavs Hospital

🇳🇴

Trondheim, Norway

© Copyright 2025. All Rights Reserved by MedPath